The price of Elanco Animal Health Inc (NYSE:ELAN) shares last traded on Wall Street rose 0.39% to $15.49.
ELAN stock price is now -2.02% away from the 50-day moving average and 21.66% away from the 200-day moving average. The market capitalization of the company currently stands at $7.64B.
With the price target enhanced from $13 to $20, Stifel Upgraded its rating from Hold to Buy for Elanco Animal Health Inc (NYSE: ELAN). On December 19, 2023, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $17, while ‘Morgan Stanley’ rates the stock as ‘Overweight’
In other news, DOYLE WILLIAM F, Director bought 15,000 shares of the company’s stock on Mar 08 ’24. The stock was bought for $244,500 at an average price of $16.30. Upon completion of the transaction, the Director now directly owns 61,330 shares in the company, valued at $0.95 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 08 ’24, Director Harrington Michael J bought 3,100 shares of the business’s stock. A total of $50,494 was incurred on buying the stock at an average price of $16.29. This leaves the insider owning 77,594 shares of the company worth $1.2 million. A total of 0.98% of the company’s stock is owned by insiders.
During the past 12 months, Elanco Animal Health Inc has had a low of $7.88 and a high of $16.88. As of last week, the company has a debt-to-equity ratio of 0.95, a current ratio of 2.75, and a quick ratio of 1.35. The fifty day moving average price for ELAN is $15.81 and a two-hundred day moving average price translates $12.73 for the stock.
The latest earnings results from Elanco Animal Health Inc (NYSE: ELAN) was released for Dec, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.08, missing analysts’ expectations of $0.11 by -0.03. This compares to -$0.11 EPS in the same period last year. The net profit margin was -27.87% and return on equity was -18.22% for ELAN. The company reported revenue of $1.03 billion for the quarter, compared to $984.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.18 percent. For the current quarter, analysts expect ELAN to generate $1.17B in revenue.
Elanco Animal Health Inc(ELAN) Company Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
